ES2170759T3 - Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos. - Google Patents

Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.

Info

Publication number
ES2170759T3
ES2170759T3 ES94115961T ES94115961T ES2170759T3 ES 2170759 T3 ES2170759 T3 ES 2170759T3 ES 94115961 T ES94115961 T ES 94115961T ES 94115961 T ES94115961 T ES 94115961T ES 2170759 T3 ES2170759 T3 ES 2170759T3
Authority
ES
Spain
Prior art keywords
galantamine
medications
derivatives
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94115961T
Other languages
English (en)
Inventor
Raymond W Kosley Jr
Larry Davis
Veronica Taberna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2170759T3 publication Critical patent/ES2170759T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ESTA SOLICITUD SE REFIERE A COMPUESTOS DE LA FORMULA, EN LA QUE R1, R2 Y R3 ESTAN DEFINIDOS EN ELLA, CUYOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO DE DISFUNCION DE LA MEMORIA, CARACTERIZADA POR FUNCION COLINERGICA DISMINUIDA, COMPOSICIONES FARMACEUTICAS QUE CONTIENEN LOS COMPUESTOS Y METODOS PARA HACER Y USAR LOS COMPUESTOS.
ES94115961T 1993-10-15 1994-10-10 Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos. Expired - Lifetime ES2170759T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,444 US6316439B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
ES2170759T3 true ES2170759T3 (es) 2002-08-16

Family

ID=22477461

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94115961T Expired - Lifetime ES2170759T3 (es) 1993-10-15 1994-10-10 Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.

Country Status (23)

Country Link
US (1) US6316439B1 (es)
EP (1) EP0649846B1 (es)
JP (1) JP2664343B2 (es)
KR (1) KR100227957B1 (es)
CN (1) CN1039910C (es)
AT (1) ATE211474T1 (es)
AU (1) AU696170B2 (es)
CA (1) CA2118172C (es)
CZ (1) CZ283731B6 (es)
DE (1) DE69429570T2 (es)
DK (1) DK0649846T3 (es)
EG (1) EG20726A (es)
ES (1) ES2170759T3 (es)
FI (1) FI108722B (es)
IL (1) IL111275A (es)
NO (1) NO307464B1 (es)
NZ (1) NZ264682A (es)
PL (1) PL177549B1 (es)
PT (1) PT649846E (es)
RO (1) RO114134B1 (es)
RU (1) RU2109743C1 (es)
TW (1) TW289754B (es)
ZA (1) ZA948061B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
MXPA02005667A (es) * 1999-12-10 2004-09-10 Bonnie Davis Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
US6849638B2 (en) * 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US20050142193A1 (en) * 2003-12-31 2005-06-30 Lijuan Tang Galantamine formulations
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
EP2425845A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
DE602006016441D1 (de) * 2005-05-13 2010-10-07 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
CN102007129B (zh) 2008-04-14 2014-05-07 神经动力生命科学公司 用作治疗人类脑疾病的前药的雪花胺衍生物
JP2013500268A (ja) * 2009-07-23 2013-01-07 シャイア エルエルシー ガランタミンアミノ酸およびペプチドプロドラッグならびにその使用
JP6906955B2 (ja) * 2014-05-16 2021-07-21 シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ 認知症の症状が観察されない患者の認知症の発症を遅らせるための薬剤
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
US12551491B1 (en) * 2025-07-23 2026-02-17 Alpha Cognition Inc. Dosage regimens for benzgalantamine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
KR100195399B1 (ko) * 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
DE69229781T2 (de) 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
NO943895L (no) 1995-04-18
FI944823L (fi) 1995-04-16
IL111275A0 (en) 1994-12-29
NO307464B1 (no) 2000-04-10
JPH07188239A (ja) 1995-07-25
ATE211474T1 (de) 2002-01-15
AU7581394A (en) 1995-05-04
PT649846E (pt) 2002-06-28
EP0649846B1 (en) 2002-01-02
RU2109743C1 (ru) 1998-04-27
KR950011445A (ko) 1995-05-15
PL305457A1 (en) 1995-04-18
CN1039910C (zh) 1998-09-23
RU94036745A (ru) 1996-12-10
CA2118172C (en) 2000-01-04
TW289754B (es) 1996-11-01
CZ283731B6 (cs) 1998-06-17
CA2118172A1 (en) 1995-04-16
FI944823A0 (fi) 1994-10-13
FI108722B (fi) 2002-03-15
AU696170B2 (en) 1998-09-03
CZ254594A3 (en) 1995-07-12
NZ264682A (en) 1995-07-26
NO943895D0 (no) 1994-10-14
DE69429570T2 (de) 2002-08-29
CN1108657A (zh) 1995-09-20
EP0649846A1 (en) 1995-04-26
RO114134B1 (ro) 1999-01-29
EG20726A (en) 1999-12-29
IL111275A (en) 2003-01-12
KR100227957B1 (ko) 1999-11-01
JP2664343B2 (ja) 1997-10-15
PL177549B1 (pl) 1999-12-31
DE69429570D1 (de) 2002-02-07
US6316439B1 (en) 2001-11-13
ZA948061B (en) 1995-06-06
DK0649846T3 (da) 2002-04-15

Similar Documents

Publication Publication Date Title
ES2170759T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
ES2171428T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
UY24244A1 (es) Derivados bicíclicos y policíclicos de isotiazolona
ES2158876T3 (es) Derivado de galantamina, un procedimiento para su preparacion y su utilizacion como medicamento.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
UY28150A1 (es) Agentes terapeuticos
ECSP034444A (es) Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
AR020020A1 (es) Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
CL2003002770A1 (es) Compuestos derivados de pirrol e imiddazol; composiciones farmaceuticas que los contienen; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de enfermedades que estan asociadas con la modulacion de los receptores a canabinoides
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
AR028948A1 (es) Compuestos novedosos
ES2147739T3 (es) Fosfonooximetil-eteres de derivados de taxano.
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ES2191320T3 (es) Derivados de piperazina y su uso como agentes anti-inflamatorios.
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
ES2156024T3 (es) Derivados siliciados de benzo-x-azoles filtros, composiciones cosmeticas fotoprotectoras que los contienen y utilizaciones.
BRPI0414858A (pt) métodos para preparação de corpos de óleo compreendendo ingredientes ativos
UY28736A1 (es) Derivados de quinazolina
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
PA8487701A1 (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 649846

Country of ref document: ES